Protein Tyrosine Kinases: From Inhibitors to Useful Drugs

ISBN-13: 9781617375347 / Angielski / Miękka / 2010 / 290 str.

Doriano Fabbro; Frank McCormick

Opis

Leading researchers, from the Novartis group that pioneered Gleevec/Glivec and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors."

Spis treści

Protein Tyrosine Kinases as Targets for Cancer and Other Indications Mark Pearson, Carlos García-Echeverría, and Doriano Fabbro Inhibitors of Signaling Interfaces: Targeting Src Homology 2 Domains in Drug Discovery Carlos García-Echeverría PI3-Kinase Inhibition: A Target for Therapeutic Intervention Peter M. Finan and Stephen G. Ward Src as a Target for Pharmaceutical Intervention: Potential and Limitations Mira Susa, Martin Missbach, Rainer Gamse, Michaela Kneissel, Thomas Buhl, Jürg A. Gasser, Markus Glatt, Terence O'Reilly, Anna Teti, and Jonathan Green Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target in Leukemia Blanca Scheijen and James D. Griffin JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma Renate Burger and Martin Gramatzki Glivec® (Gleevec®, Imatinib, STI571): A Targeted Therapy for Chronic Myelogenous Leukemia Elisabeth Buchdunger and Renaud Capedeville Platelet-Derived Growth Factor: Normal Function, Role in Disease, and Application of PDGF Antagonists Tobias Sjöblom, Kristian Pietras, Arne Östman, and Carl-Henrik Heldin Structural Biology of Protein Tyrosine Kinases Sandra W. Cowan-Jacob, Paul Ramage, Wilhelm Stark, Gabriele Fendrich, and Wolfgang Jahnke Testing of Signal Transduction Inhibitors in Animal Models of Cancer Terence O'Reilly and Robert Cozens Phosphoproteomics in Drug Discovery and Development Michel F. Moran, Jarrod A. Marto, Cynthia J. Brame, Olga Ornatsky, Mark M. Ross, Leticia M. Toledo-Sherman, Alfredo C. Castro, Brett Larsen, Henry Duewel, Christopher Hosfield, Christopher Orsi, Thodoros Topaloglou, Daniel Figeys, Jarrod A. Caldwell-Busby, and David R. Stover Index

Blurb

Protein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivec™ and from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.
Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs.